HEC Says Axed Novartis Patent Win 'Not Remotely Certworthy'
Chinese pharmaceutical company HEC Pharm told the U.S. Supreme Court Friday that a Federal Circuit opinion invalidating Novartis Pharmaceuticals' patent on multiple sclerosis drug Gilenya is "not remotely certworthy," arguing that...To view the full article, register now.
Already a subscriber? Click here to view full article